NEWS legal form changed ByOncoscience 22. August 201717. July 2025 We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson. Ähnliche Beiträge
NEWS Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer ByOncoscience 28. May 202217. July 2025
NEWS The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively ByOncoscience 26. October 200717. July 2025
NEWS Oncoscience AG announces completion of patient enrollment in phase III trial of NIMOTUZUMAB, in first line treatment of children with inoperable brain cancer ByOncoscience 12. September 200717. July 2025
NEWS Oncoscience AG announced a change in the board of directors ByOncoscience 15. October 200417. July 2025
NEWS Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. ByOncoscience 17. November 201717. July 2025
NEWS Innokeys Pte. Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG ByOncoscience 22. July 201517. July 2025
